Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - dexamfetamine sulfate -

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - dexamethasone - implant in applicator - dexamethasone 0.7 mg - dexamethasone - dexamethasone - ozurdex is indicated for the treatment of adult patients with:• diabetic macular oedema (dme)• macular oedema following either branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo).• inflammation of the posterior segment of the eye presenting as non-infectious uveitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dexamethasone, quantity: 700 microgram - implant - excipient ingredients: polyglactin - ozurdex is indicated for the treatment of:,- diabetic macular oedema (dme),- macular oedema due to branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo).,- non-infectious uveitis affecting the posterior segment of the eye. ozurdex is indicated for the treatment of diabetic macular oedema (dme).

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml - solution for injection - 4 mg/ml - active: dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml excipient: citric acid monohydrate creatinin sodium citrate sodium hydroxide water for injection - replacement therapy - adrenocortical insufficiency dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy. it should be supplemented with salt and or a mineralocorticoid. when so supplemented dexamethasone is indicated in: · acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy. relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available. primary and secondary adrenocortical insufficiency.

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml - solution for injection - 8 mg/2ml - active: dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml excipient: citric acid monohydrate creatinin sodium citrate sodium hydroxide water for injection - replacement therapy - adrenocortical insufficiency dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy. it should be supplemented with salt and or a mineralocorticoid. when so supplemented dexamethasone is indicated in: · acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy. relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available. primary and secondary adrenocortical insufficiency.

Ireland - English - HPRA (Health Products Regulatory Authority)

alfasan nederland b.v - dexamethasone - solution for injection - 2 mg/ml - dexamethasone - bovine, canine, equine - food, feline - corticosteroid

Ireland - English - HPRA (Health Products Regulatory Authority)

alfasan nederland b.v - dexamethasone sodium phosphate - solution for injection - 2 milligram(s)/millilitre - dexamethasone - cats, cattle, dogs, horses - corticosteroid

Canada - English - Health Canada

strides pharma canada inc - dexamethasone phosphate (dexamethasone sodium phosphate) - solution - 4mg - dexamethasone phosphate (dexamethasone sodium phosphate) 4mg - adrenals

Canada - English - Health Canada

strides pharma canada inc - dexamethasone phosphate (dexamethasone sodium phosphate) - solution - 10mg - dexamethasone phosphate (dexamethasone sodium phosphate) 10mg - adrenals

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

balkanpharma-razgrad ad - dexamethasone - tablets - 0,5mg